HPV16 E7 long peptide vaccine

HPV16 E7 long peptide vaccine is a therapeutic peptide vaccine developed by Zhongao Biomedical Technology for the treatment of HPV16-related malignancies, including cervical cancer. The vaccine utilizes long synthetic peptides derived from the HPV16 E7 oncoprotein, which are designed to contain multiple CD4+ and CD8+ T-cell epitopes. Its mechanism of action involves the induction of a robust, tumor-specific cellular immune response; specifically, it aims to activate cytotoxic T lymphocytes (CTLs) that can recognize and eliminate HPV16-positive tumor cells. In preclinical research, the vaccine is often evaluated using the TC-1 tumor model and has been studied in combination with Caerin peptides (such as Caerin 1.1 or 1.9) to enhance its immunogenicity and therapeutic efficacy by modulating the immunosuppressive tumor microenvironment.

Other names

E7 peptide vaccineE-7 peptide vaccineE 7 peptide vaccineHPV16 E7 long peptide vaccineHPV-16 E7 long peptide vaccineHPV 16 E7 long peptide vaccine